3-Iodobenzylguanidine
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Desipramine.
4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Desipramine.
Abiraterone
The serum concentration of Desipramine can be increased when it is combined with Abiraterone.
Advertisement
Acenocoumarol
Desipramine may increase the anticoagulant activities of Acenocoumarol.
Acepromazine
The risk or severity of adverse effects can be increased when Desipramine is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Desipramine is combined with Aceprometazine.
Advertisement
Acetaminophen
The metabolism of Acetaminophen can be decreased when combined with Desipramine.
Acetophenazine
The risk or severity of adverse effects can be increased when Desipramine is combined with Acetophenazine.
Acetylcholine
The metabolism of Acetylcholine can be decreased when combined with Desipramine.
Advertisement
Acetylcholine Chloride
The metabolism of Acetylcholine can be decreased when combined with Desipramine.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Desipramine.
Ajmaline
The metabolism of Ajmaline can be decreased when combined with Desipramine.
Albuterol
The risk or severity of adverse effects can be increased when Desipramine is combined with Salbutamol.
Alfaxalone
The risk or severity of adverse effects can be increased when Desipramine is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Desipramine.
Almotriptan
The risk or severity of adverse effects can be increased when Almotriptan is combined with Desipramine.
Alogliptin
The serum concentration of Desipramine can be increased when it is combined with Alogliptin.
alpha 1-Antitrypsin
The serum concentration of Desipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.
Alpha 1-Proteinase Inhibitor, Human
The serum concentration of Desipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.
Alphaprodine
The risk or severity of adverse effects can be increased when Desipramine is combined with Alphaprodine.
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Desipramine.
Alprenolol
The metabolism of Alprenolol can be decreased when combined with Desipramine.
Altretamine
Altretamine may increase the orthostatic hypotensive activities of Desipramine.
Aminopyrine
The metabolism of Aminophenazone can be decreased when combined with Desipramine.
Amiodarone
The metabolism of Desipramine can be decreased when combined with Amiodarone.
Amisulpride
The risk or severity of adverse effects can be increased when Desipramine is combined with Amisulpride.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Desipramine.
Amobarbital
The metabolism of Desipramine can be increased when combined with Amobarbital.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Desipramine.
Amphetamine
The metabolism of Amphetamine can be decreased when combined with Desipramine.
Amprenavir
The serum concentration of Desipramine can be increased when it is combined with Amprenavir.
Amsacrine
The metabolism of Amsacrine can be decreased when combined with Desipramine.
Anagrelide
Desipramine may increase the QTc-prolonging activities of Anagrelide.
Antipyrine
The metabolism of Antipyrine can be decreased when combined with Desipramine.
Antithrombin III
The serum concentration of Desipramine can be increased when it is combined with Antithrombin III human.
Antithrombin III, Human
The serum concentration of Desipramine can be increased when it is combined with Antithrombin III human.
Apalutamide
The serum concentration of Desipramine can be decreased when it is combined with Apalutamide.
Apixaban
The serum concentration of Desipramine can be increased when it is combined with Apixaban.
Apomorphine
Desipramine may decrease the antihypertensive activities of Apomorphine.
Apraclonidine
Desipramine may decrease the antihypertensive activities of Apraclonidine.
Aprindine
The metabolism of Aprindine can be decreased when combined with Desipramine.
Aprotinin
The serum concentration of Desipramine can be increased when it is combined with Aprotinin.
Arbutamine
The risk or severity of adverse effects can be increased when Desipramine is combined with Arbutamine.
Arformoterol
The metabolism of Arformoterol can be decreased when combined with Desipramine.
Argatroban
The serum concentration of Desipramine can be increased when it is combined with Argatroban.
Argatroban Anhydrous
The serum concentration of Desipramine can be increased when it is combined with Argatroban.
Aripiprazole
The serum concentration of Aripiprazole can be increased when it is combined with Desipramine.
Armodafinil
The metabolism of Desipramine can be decreased when combined with Armodafinil.
Arsenic Trioxide
Desipramine may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Desipramine may increase the QTc-prolonging activities of Artemether.
Artesunate
The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Desipramine resulting in a loss in efficacy.
Articaine
The risk or severity of adverse effects can be increased when Desipramine is combined with Articaine.
Asenapine
Desipramine may increase the QTc-prolonging activities of Asenapine.
Astemizole
The metabolism of Astemizole can be decreased when combined with Desipramine.
Asunaprevir
The serum concentration of Desipramine can be increased when it is combined with Asunaprevir.
Atazanavir
The serum concentration of Desipramine can be increased when it is combined with Atazanavir.
Atomoxetine
The metabolism of Desipramine can be decreased when combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Desipramine is combined with Atorvastatin.
Azelastine
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Azithromycin
The metabolism of Desipramine can be decreased when combined with Azithromycin.
Baclofen
The risk or severity of adverse effects can be increased when Baclofen is combined with Desipramine.
Bambuterol
The risk or severity of adverse effects can be increased when Desipramine is combined with Bambuterol.
Barbexaclone
The metabolism of Desipramine can be increased when combined with Barbexaclone.
Barbital
The metabolism of Desipramine can be increased when combined with Barbital.
Bedaquiline
Desipramine may increase the QTc-prolonging activities of Bedaquiline.
Benazepril
The serum concentration of Desipramine can be increased when it is combined with Benazepril.
Benoxinate
The risk or severity of adverse effects can be increased when Desipramine is combined with Oxybuprocaine.
Benperidol
The risk or severity of adverse effects can be increased when Desipramine is combined with Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Desipramine is combined with Benzocaine.
Benzphetamine
Desipramine may decrease the antihypertensive activities of Benzphetamine.
Benztropine
The metabolism of Benzatropine can be decreased when combined with Desipramine.
Benzyl Alcohol
The metabolism of Benzyl alcohol can be decreased when combined with Desipramine.
Bepridil
The metabolism of Bepridil can be decreased when combined with Desipramine.
Betaxolol
The metabolism of Betaxolol can be decreased when combined with Desipramine.
Bethanidine
Desipramine may decrease the antihypertensive activities of Bethanidine.
Bisoprolol
The metabolism of Bisoprolol can be decreased when combined with Desipramine.
Bivalirudin
The serum concentration of Desipramine can be increased when it is combined with Bivalirudin.
Boceprevir
The serum concentration of Desipramine can be increased when it is combined with Boceprevir.
Bortezomib
The metabolism of Desipramine can be decreased when combined with Bortezomib.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Desipramine.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Desipramine.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Desipramine.
Brexpiprazole
The serum concentration of Brexpiprazole can be increased when it is combined with Desipramine.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Brivaracetam
The metabolism of Brivaracetam can be decreased when combined with Desipramine.
Bromazepam
The risk or severity of adverse effects can be increased when Bromazepam is combined with Desipramine.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Desipramine.
Bromperidol
The risk or severity of adverse effects can be increased when Desipramine is combined with Bromperidol.
Brompheniramine
The metabolism of Brompheniramine can be decreased when combined with Desipramine.
Brotizolam
The risk or severity of adverse effects can be increased when Desipramine is combined with Brotizolam.
Bupivacaine
The metabolism of Bupivacaine can be decreased when combined with Desipramine.
Buprenorphine
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion
The metabolism of Desipramine can be decreased when combined with Bupropion.
Buspirone
The risk or severity of adverse effects can be increased when Buspirone is combined with Desipramine.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Desipramine.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Desipramine.
Butamben
The risk or severity of adverse effects can be increased when Desipramine is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Desipramine is combined with Butethal.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Desipramine.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Desipramine.
Caffeine
The metabolism of Desipramine can be decreased when combined with Caffeine.
Captopril
The serum concentration of Desipramine can be increased when it is combined with Captopril.
Carbamazepine
The metabolism of Desipramine can be increased when combined with Carbamazepine.
Carbinoxamine
The metabolism of Carbinoxamine can be decreased when combined with Desipramine.
Cariprazine
The metabolism of Cariprazine can be decreased when combined with Desipramine.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Desipramine.
Carteolol
The metabolism of Carteolol can be decreased when combined with Desipramine.
Carvedilol
The metabolism of Carvedilol can be decreased when combined with Desipramine.
Celecoxib
The metabolism of Desipramine can be decreased when combined with Celecoxib.
Celiprolol
The risk or severity of adverse effects can be increased when Desipramine is combined with Celiprolol.
Cephalexin
The metabolism of Cephalexin can be decreased when combined with Desipramine.
CEPHALEXIN ANHYDROUS
The metabolism of Cephalexin can be decreased when combined with Desipramine.
Ceritinib
Desipramine may increase the QTc-prolonging activities of Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Desipramine.
Cetirizine
The risk or severity of adverse effects can be increased when Cetirizine is combined with Desipramine.
Cevimeline
The metabolism of Cevimeline can be decreased when combined with Desipramine.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Desipramine is combined with Chloral hydrate.
Chloramphenicol
The metabolism of Desipramine can be decreased when combined with Chloramphenicol.
Chlordiazepoxide
The metabolism of Chlordiazepoxide can be decreased when combined with Desipramine.
Chlormethiazole
The metabolism of clomethiazole can be decreased when combined with Desipramine.
Chlormezanone
The risk or severity of adverse effects can be increased when Desipramine is combined with Chlormezanone.
Chloroprocaine
The risk or severity of adverse effects can be increased when Desipramine is combined with Chloroprocaine.
Chloroquine
The metabolism of Chloroquine can be decreased when combined with Desipramine.
Chlorpheniramine
The metabolism of Chlorphenamine can be decreased when combined with Desipramine.
CHLORPHENIRAMINE POLISTIREX
The metabolism of Chlorphenamine can be decreased when combined with Desipramine.
Chlorpromazine
The metabolism of Desipramine can be decreased when combined with Chlorpromazine.
Chlorprothixene
The risk or severity of adverse effects can be increased when Desipramine is combined with Chlorprothixene.
Chlorzoxazone
The metabolism of Chlorzoxazone can be decreased when combined with Desipramine.
Cholecalciferol
The metabolism of Desipramine can be decreased when combined with Cholecalciferol.
Cholesterol
The serum concentration of Desipramine can be increased when it is combined with Cholesterol.
Cilastatin
The serum concentration of Desipramine can be increased when it is combined with Cilastatin.
Cilazapril
The serum concentration of Desipramine can be increased when it is combined with Cilazapril.
Cilostazol
The serum concentration of Cilostazol can be increased when it is combined with Desipramine.
Cimetidine
The metabolism of Desipramine can be decreased when combined with Cimetidine.
Cinacalcet
The serum concentration of Desipramine can be increased when it is combined with Cinacalcet.
Cinnarizine
The metabolism of Cinnarizine can be decreased when combined with Desipramine.
Ciprofloxacin
Desipramine may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Desipramine may increase the QTc-prolonging activities of Cisapride.
Citalopram
The risk or severity of adverse effects can be increased when Desipramine is combined with Citalopram.
Clarithromycin
Desipramine may increase the QTc-prolonging activities of Clarithromycin.
Clemastine
The metabolism of Desipramine can be decreased when combined with Clemastine.
Clenbuterol
The risk or severity of adverse effects can be increased when Desipramine is combined with Clenbuterol.
Clevidipine
The metabolism of Clevidipine can be decreased when combined with Desipramine.
Clevidipine butyrate
The metabolism of Clevidipine can be decreased when combined with Desipramine.
Clidinium
The risk or severity of adverse effects can be increased when Clidinium is combined with Desipramine.
Clidinium bromide
The risk or severity of adverse effects can be increased when Clidinium is combined with Desipramine.
Clobazam
The metabolism of Desipramine can be decreased when combined with Clobazam.
Clomipramine
The risk or severity of adverse effects can be increased when Desipramine is combined with Clomipramine.
Clonazepam
The risk or severity of adverse effects can be increased when Clonazepam is combined with Desipramine.
Clonidine
Desipramine may decrease the antihypertensive activities of Clonidine.
Clopidogrel
The metabolism of Clopidogrel can be decreased when combined with Desipramine.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Desipramine.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Desipramine.
Clotiazepam
The metabolism of Clotiazepam can be decreased when combined with Desipramine.
Clotrimazole
The metabolism of Desipramine can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Clozapine can be decreased when combined with Desipramine.
Cobicistat
The serum concentration of Desipramine can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Desipramine can be decreased when combined with Cocaine.
Codeine
The therapeutic efficacy of Codeine can be decreased when used in combination with Desipramine.
Codeine Anhydrous
The therapeutic efficacy of Codeine can be decreased when used in combination with Desipramine.
CODEINE POLISTIREX
The therapeutic efficacy of Codeine can be decreased when used in combination with Desipramine.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Desipramine.
Crizotinib
Desipramine may increase the QTc-prolonging activities of Crizotinib.
Cyamemazine
The risk or severity of adverse effects can be increased when Desipramine is combined with Cyamemazine.
Cyclizine
The risk or severity of adverse effects can be increased when Desipramine is combined with Cyclizine.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desipramine.
Cyclophosphamide
The metabolism of Cyclophosphamide can be decreased when combined with Desipramine.
Cyclophosphamide Anhydrous
The metabolism of Cyclophosphamide can be decreased when combined with Desipramine.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Desipramine.
Cyproterone Acetate
The serum concentration of Desipramine can be decreased when it is combined with Cyproterone acetate.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desipramine.
Dabrafenib
The serum concentration of Desipramine can be decreased when it is combined with Dabrafenib.
Dantrolene
The risk or severity of adverse effects can be increased when Desipramine is combined with Dantrolene.
Dapagliflozin
The metabolism of Dapagliflozin can be decreased when combined with Desipramine.
Dapiprazole
The risk or severity of adverse effects can be increased when Desipramine is combined with Dapiprazole.
Darifenacin
The metabolism of Desipramine can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Desipramine can be increased when it is combined with Darunavir.
Dasabuvir
The metabolism of Dasabuvir can be decreased when combined with Desipramine.
Debrisoquin
The metabolism of Debrisoquin can be decreased when combined with Desipramine.
Deferasirox
The serum concentration of Desipramine can be increased when it is combined with Deferasirox.
Delavirdine
The metabolism of Desipramine can be decreased when combined with Delavirdine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Desipramine.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Desipramine.
Desmopressin
The risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.
Desvenlafaxine
The risk or severity of adverse effects can be increased when Desipramine is combined with Desvenlafaxine.
Deutetrabenazine
The metabolism of Deutetrabenazine can be decreased when combined with Desipramine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desipramine.
Dexchlorpheniramine maleate
The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Desipramine.
Dexfenfluramine
The metabolism of Dexfenfluramine can be decreased when combined with Desipramine.
Dexmedetomidine
Desipramine may decrease the antihypertensive activities of Dexmedetomidine.
Dexmethylphenidate
The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Desipramine.
Dextroamphetamine
The metabolism of Dextroamphetamine can be decreased when combined with Desipramine.
Dextromethorphan
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Desipramine.
Dextromoramide
The risk or severity of adverse effects can be increased when Desipramine is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Desipramine is combined with Dezocine.
Diazepam
The metabolism of Diazepam can be decreased when combined with Desipramine.
Dibucaine
The risk or severity of adverse effects can be increased when Desipramine is combined with Cinchocaine.
Diclofenac
The metabolism of Diclofenac can be decreased when combined with Desipramine.
Dicumarol
Desipramine may increase the anticoagulant activities of Dicoumarol.
Diethylpropion
Desipramine may increase the stimulatory activities of Diethylpropion.
Difenoxin
The risk or severity of adverse effects can be increased when Desipramine is combined with Difenoxin.
Dihydrocodeine
The metabolism of Dihydrocodeine can be decreased when combined with Desipramine.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Desipramine.
Diltiazem
The metabolism of Diltiazem can be decreased when combined with Desipramine.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Desipramine.
Diphenhydramine
The metabolism of Diphenhydramine can be decreased when combined with Desipramine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desipramine.
Dipivefrin
Desipramine may decrease the antihypertensive activities of Dipivefrin.
Disopyramide
Desipramine may increase the QTc-prolonging activities of Disopyramide.
Dobutamine
The risk or severity of adverse effects can be increased when Desipramine is combined with Dobutamine.
Dofetilide
Desipramine may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
The metabolism of Dolasetron can be decreased when combined with Desipramine.
Domperidone
Desipramine may increase the QTc-prolonging activities of Domperidone.
Donepezil
The metabolism of Donepezil can be decreased when combined with Desipramine.
Dopamine
The metabolism of Dopamine can be decreased when combined with Desipramine.
Dothiepin
The metabolism of Desipramine can be decreased when combined with Dosulepin.
Doxazosin
The metabolism of Doxazosin can be decreased when combined with Desipramine.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Desipramine.
Doxorubicin
The metabolism of Doxorubicin can be decreased when combined with Desipramine.
Doxorubicin Hydrochloride
The metabolism of Doxorubicin can be decreased when combined with Desipramine.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Dronedarone
Desipramine may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Droxidopa
Desipramine may decrease the antihypertensive activities of Droxidopa.
Duloxetine
Duloxetine may increase the serotonergic activities of Desipramine.
Dyclonine
The risk or severity of adverse effects can be increased when Desipramine is combined with Dyclonine.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Desipramine.
Efavirenz
The metabolism of Desipramine can be decreased when combined with Efavirenz.
Eletriptan
The risk or severity of adverse effects can be increased when Eletriptan is combined with Desipramine.
Eliglustat
The serum concentration of Eliglustat can be increased when it is combined with Desipramine.
Enalapril
The serum concentration of Desipramine can be increased when it is combined with Enalapril.
Enalaprilat
The serum concentration of Desipramine can be increased when it is combined with Enalaprilat.
Enalaprilat Anhydrous
The serum concentration of Desipramine can be increased when it is combined with Enalaprilat.
Enasidenib
The metabolism of Enasidenib can be decreased when combined with Desipramine.
Encainide
The metabolism of Encainide can be decreased when combined with Desipramine.
Enflurane
The risk or severity of adverse effects can be increased when Desipramine is combined with Enflurane.
Entacapone
The risk or severity of adverse effects can be increased when Entacapone is combined with Desipramine.
Epigallocatechin Gallate
The serum concentration of Desipramine can be increased when it is combined with Epigallocatechin Gallate.
Epinastine
The metabolism of Epinastine can be decreased when combined with Desipramine.
Epinephrine
Desipramine may decrease the antihypertensive activities of Epinephrine.
ergoloid mesylates, USP
The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desipramine.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Desipramine.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Desipramine.
Erlotinib
The metabolism of Erlotinib can be decreased when combined with Desipramine.
Erythromycin
The metabolism of Erythromycin can be decreased when combined with Desipramine.
Escitalopram
The risk or severity of adverse effects can be increased when Desipramine is combined with Escitalopram.
Eslicarbazepine Acetate
The metabolism of Desipramine can be decreased when combined with Eslicarbazepine acetate.
Esomeprazole
The metabolism of Desipramine can be decreased when combined with Esomeprazole.
Estazolam
The risk or severity of adverse effects can be increased when Estazolam is combined with Desipramine.
Estrone
The metabolism of Estrone can be decreased when combined with Desipramine.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Desipramine.
Ethanol
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Desipramine is combined with Ethchlorvynol.
Ethosuximide
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Desipramine.
Ethotoin
The risk or severity of adverse effects can be increased when Ethotoin is combined with Desipramine.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Desipramine is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Desipramine is combined with Ethyl loflazepate.
Ethylmorphine
The metabolism of Ethylmorphine can be decreased when combined with Desipramine.
Etidocaine
The risk or severity of adverse effects can be increased when Desipramine is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Desipramine is combined with Etifoxine.
Etomidate
Desipramine may decrease the antihypertensive activities of Etomidate.
Etoricoxib
The metabolism of Etoricoxib can be decreased when combined with Desipramine.
Etravirine
The metabolism of Desipramine can be decreased when combined with Etravirine.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Desipramine.
Ezogabine
The risk or severity of adverse effects can be increased when Desipramine is combined with Ezogabine.
Felbamate
The risk or severity of adverse effects can be increased when Felbamate is combined with Desipramine.
Fenoterol
The risk or severity of adverse effects can be increased when Desipramine is combined with Fenoterol.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Desipramine.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desipramine.
Fexofenadine
The risk or severity of adverse effects can be increased when Fexofenadine is combined with Desipramine.
Fibrinolysis Inhibitor
The serum concentration of Desipramine can be increased when it is combined with Aprotinin.
Fingolimod
The metabolism of Fingolimod can be decreased when combined with Desipramine.
Flecainide
The metabolism of Flecainide can be decreased when combined with Desipramine.
Flibanserin
The risk or severity of adverse effects can be increased when Desipramine is combined with Flibanserin.
Fluconazole
The metabolism of Desipramine can be decreased when combined with Fluconazole.
Fluindione
Desipramine may increase the anticoagulant activities of Fluindione.
Flunarizine
The metabolism of Flunarizine can be decreased when combined with Desipramine.
Flunitrazepam
The metabolism of Flunitrazepam can be decreased when combined with Desipramine.
Fluoxetine
The risk or severity of adverse effects can be increased when Fluoxetine is combined with Desipramine.
Flupenthixol
Desipramine may increase the QTc-prolonging activities of Flupentixol.
Fluphenazine
The metabolism of Fluphenazine can be decreased when combined with Desipramine.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Desipramine.
Fluspirilene
The risk or severity of adverse effects can be increased when Desipramine is combined with Fluspirilene.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Desipramine.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Desipramine.
Fluvoxamine
The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desipramine.
Formoterol
The metabolism of Formoterol can be decreased when combined with Desipramine.
Fosamprenavir
The serum concentration of Desipramine can be increased when it is combined with Fosamprenavir.
Fosinopril
The serum concentration of Desipramine can be increased when it is combined with Fosinopril.
Fosphenytoin
The metabolism of Desipramine can be increased when combined with Fosphenytoin.
Fospropofol
The risk or severity of adverse effects can be increased when Desipramine is combined with Fospropofol.
Frovatriptan
The risk or severity of adverse effects can be increased when Frovatriptan is combined with Desipramine.
Furazolidone
Furazolidone may increase the serotonergic activities of Desipramine.
Gabapentin
The risk or severity of adverse effects can be increased when Gabapentin is combined with Desipramine.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Desipramine is combined with Gabapentin Enacarbil.
Gadobenate
Desipramine may increase the QTc-prolonging activities of Gadobenic acid.
Galantamine
The metabolism of Galantamine can be decreased when combined with Desipramine.
Gefitinib
The metabolism of Gefitinib can be decreased when combined with Desipramine.
Gemfibrozil
The metabolism of Desipramine can be decreased when combined with Gemfibrozil.
Gemifloxacin
Desipramine may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Desipramine may increase the QTc-prolonging activities of Gemifloxacin.
Glutethimide
The risk or severity of adverse effects can be increased when Desipramine is combined with Glutethimide.
Goserelin
Desipramine may increase the QTc-prolonging activities of Goserelin.
Granisetron
The metabolism of Granisetron can be decreased when combined with Desipramine.
Guanabenz
Desipramine may decrease the antihypertensive activities of Guanabenz.
Guanfacine
Desipramine may decrease the antihypertensive activities of Guanfacine.
Halazepam
The risk or severity of adverse effects can be increased when Desipramine is combined with Halazepam.
Halofantrine
The metabolism of Halofantrine can be decreased when combined with Desipramine.
Haloperidol
The metabolism of Desipramine can be decreased when combined with Haloperidol.
Halothane
The metabolism of Halothane can be decreased when combined with Desipramine.
Heroin
The risk or severity of adverse effects can be increased when Desipramine is combined with Heroin.
Hexobarbital
The metabolism of Desipramine can be increased when combined with Hexobarbital.
Hydrocodone
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone
The metabolism of Hydromorphone can be decreased when combined with Desipramine.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Hypoxis hemerocallidea root extract
The metabolism of Desipramine can be increased when combined with St. John's Wort.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Desipramine.
Ibutilide
Desipramine may increase the QTc-prolonging activities of Ibutilide.
Idarubicin
The metabolism of Idarubicin can be decreased when combined with Desipramine.
Ifosfamide
The metabolism of Ifosfamide can be decreased when combined with Desipramine.
Iloperidone
Desipramine may increase the QTc-prolonging activities of Iloperidone.
Imatinib
The metabolism of Imatinib can be decreased when combined with Desipramine.
Imidapril
The serum concentration of Desipramine can be increased when it is combined with Imidapril.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Desipramine.
Indacaterol
The risk or severity of adverse effects can be increased when Desipramine is combined with Indacaterol.
Indinavir
The serum concentration of Desipramine can be increased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Desipramine can be increased when it is combined with Indinavir.
Ipratropium Bromide
The metabolism of Ipratropium bromide can be decreased when combined with Desipramine.
Ipratropium Bromide Anhydrous
The metabolism of Ipratropium bromide can be decreased when combined with Desipramine.
Iproniazid
Iproniazid may increase the serotonergic activities of Desipramine.
Irinotecan
The metabolism of Irinotecan can be decreased when combined with Desipramine.
Isocarboxazid
The therapeutic efficacy of Desipramine can be increased when used in combination with Isocarboxazid.
Isoetharine
The risk or severity of adverse effects can be increased when Desipramine is combined with Isoetarine.
Isoflurane
The metabolism of Isoflurane can be decreased when combined with Desipramine.
Isoflurophate
The serum concentration of Desipramine can be increased when it is combined with Isoflurophate.
Isoniazid
The metabolism of Desipramine can be decreased when combined with Isoniazid.
Isoproterenol
The risk or severity of adverse effects can be increased when Desipramine is combined with Isoprenaline.
Ixazomib
The serum concentration of Desipramine can be increased when it is combined with Ixazomib.
Ketamine
The metabolism of Ketamine can be decreased when combined with Desipramine.
Ketazolam
The risk or severity of adverse effects can be increased when Desipramine is combined with Ketazolam.
Ketoconazole
The metabolism of Desipramine can be decreased when combined with Ketoconazole.
Labetalol
The metabolism of Labetalol can be decreased when combined with Desipramine.
Lamotrigine
The risk or severity of adverse effects can be increased when Lamotrigine is combined with Desipramine.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Desipramine.
Lenvatinib
Desipramine may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Desipramine may increase the QTc-prolonging activities of Lenvatinib.
Lepirudin
The serum concentration of Desipramine can be increased when it is combined with Lepirudin.
Letermovir
The metabolism of Letermovir can be decreased when combined with Desipramine.
Leuprolide
Desipramine may increase the QTc-prolonging activities of Leuprolide.
Levalbuterol
The risk or severity of adverse effects can be increased when Desipramine is combined with Levosalbutamol.
Levetiracetam
The risk or severity of adverse effects can be increased when Desipramine is combined with Levetiracetam.
Levobupivacaine
The risk or severity of adverse effects can be increased when Desipramine is combined with Levobupivacaine.
Levocabastine
The risk or severity of adverse effects can be increased when Desipramine is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Desipramine is combined with Levocetirizine.
Levodopa
The metabolism of Levodopa can be decreased when combined with Desipramine.
Levofloxacin
Desipramine may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Desipramine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl
The risk or severity of adverse effects can be increased when Desipramine is combined with Levomethadyl Acetate.
Levomilnacipran
The risk or severity of adverse effects can be increased when Desipramine is combined with Levomilnacipran.
Levonordefrin
Desipramine may decrease the antihypertensive activities of Levonordefrin.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Desipramine.
Levothyroxine
Levothyroxine may increase the arrhythmogenic activities of Desipramine.
Lidocaine
The metabolism of Desipramine can be decreased when combined with Lidocaine.
Linagliptin
The serum concentration of Desipramine can be increased when it is combined with Linagliptin.
Linezolid
Linezolid may increase the serotonergic activities of Desipramine.
Liothyronine
Liothyronine may increase the arrhythmogenic activities of Desipramine.
Lisdexamfetamine
Desipramine may increase the stimulatory activities of Lisdexamfetamine.
Lisdexamfetamine Dimesylate
Desipramine may increase the stimulatory activities of Lisdexamfetamine.
Lisinopril
The serum concentration of Desipramine can be increased when it is combined with Lisinopril.
Lisinopril Anhydrous
The serum concentration of Desipramine can be increased when it is combined with Lisinopril.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Desipramine.
Lithium
Lithium may increase the neurotoxic activities of Desipramine.
Lithium Cation
Lithium may increase the neurotoxic activities of Desipramine.
Lofexidine
Desipramine may decrease the antihypertensive activities of Lofexidine.
Lomustine
The metabolism of Lomustine can be decreased when combined with Desipramine.
Loperamide
The metabolism of Loperamide can be decreased when combined with Desipramine.
Lopinavir
The metabolism of Desipramine can be decreased when combined with Lopinavir.
Loratadine
The metabolism of Loratadine can be decreased when combined with Desipramine.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Desipramine.
Lorcaserin
The risk or severity of adverse effects can be increased when Desipramine is combined with Lorcaserin.
Lormetazepam
The risk or severity of adverse effects can be increased when Desipramine is combined with Lormetazepam.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Desipramine.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Desipramine.
Luliconazole
The serum concentration of Desipramine can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Desipramine can be decreased when it is combined with Lumacaftor.
Lumefantrine
Desipramine may increase the QTc-prolonging activities of Lumefantrine.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Desipramine.
Magnesium Sulfate
The therapeutic efficacy of Desipramine can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Desipramine can be increased when used in combination with Magnesium sulfate.
Malathion
The metabolism of Malathion can be decreased when combined with Desipramine.
Manidipine
The metabolism of Desipramine can be decreased when combined with Manidipine.
Maprotiline
The risk or severity of adverse effects can be increased when Maprotiline is combined with Desipramine.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Desipramine.
Melatonin
The risk or severity of adverse effects can be increased when Desipramine is combined with Melatonin.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Desipramine.
Mephentermine
Desipramine may increase the vasopressor activities of Mephentermine.
Mephenytoin
The metabolism of Mephenytoin can be decreased when combined with Desipramine.
Mephobarbital
The metabolism of Desipramine can be increased when combined with Methylphenobarbital.
Mepivacaine
The risk or severity of adverse effects can be increased when Desipramine is combined with Mepivacaine.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Desipramine.
Mequitazine
The metabolism of Mequitazine can be decreased when combined with Desipramine.
Mesoridazine
The metabolism of Mesoridazine can be decreased when combined with Desipramine.
Metaproterenol
The risk or severity of adverse effects can be increased when Desipramine is combined with Orciprenaline.
Metaraminol
Desipramine may increase the vasopressor activities of Metaraminol.
Metaxalone
The risk or severity of adverse effects can be increased when Metaxalone is combined with Desipramine.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Desipramine.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Desipramine.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Desipramine is combined with Methadyl Acetate.
Methamphetamine
Desipramine may decrease the antihypertensive activities of Methamphetamine.
Methapyrilene
The risk or severity of adverse effects can be increased when Desipramine is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Desipramine is combined with Methaqualone.
Methocarbamol
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Desipramine.
Methohexital
The metabolism of Desipramine can be increased when combined with Methohexital.
Methotrimeprazine
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxamine
Desipramine may increase the vasopressor activities of Methoxamine.
Methoxyflurane
The metabolism of Methoxyflurane can be decreased when combined with Desipramine.
Methsuximide
The risk or severity of adverse effects can be increased when Desipramine is combined with Methsuximide.
Methylene blue
Desipramine may increase the serotonergic activities of Methylene blue.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Desipramine.
Methylphenidate
The risk or severity of adverse effects can be increased when Methylphenidate is combined with Desipramine.
Methyltestosterone
The metabolism of Methyltestosterone can be decreased when combined with Desipramine.
Methyprylon
The metabolism of Methyprylon can be decreased when combined with Desipramine.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Desipramine.
Metoclopramide
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Desipramine.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Desipramine.
Metylperon
The risk or severity of adverse effects can be increased when Desipramine is combined with Melperone.
Metyrosine
The risk or severity of adverse effects can be increased when Metyrosine is combined with Desipramine.
Mexiletine
The metabolism of Desipramine can be decreased when combined with Mexiletine.
Mianserin
The metabolism of Mianserin can be decreased when combined with Desipramine.
Midazolam
The metabolism of Midazolam can be decreased when combined with Desipramine.
Midodrine
Desipramine may increase the vasopressor activities of Midodrine.
Midostaurin
The metabolism of Desipramine can be decreased when combined with Midostaurin.
Mifepristone
Mifepristone may increase the QTc-prolonging activities of Desipramine.
Milnacipran
The risk or severity of adverse effects can be increased when Desipramine is combined with Milnacipran.
Minaprine
Minaprine may increase the serotonergic activities of Desipramine.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Mirabegron
The serum concentration of Desipramine can be increased when it is combined with Mirabegron.
Mirtazapine
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Moclobemide
Moclobemide may increase the serotonergic activities of Desipramine.
Modafinil
The metabolism of Desipramine can be decreased when combined with Modafinil.
Moexipril
The serum concentration of Desipramine can be increased when it is combined with Moexipril.
Molindone
The risk or severity of adverse effects can be increased when Desipramine is combined with Molindone.
Morphine
The metabolism of Morphine can be decreased when combined with Desipramine.
Moxifloxacin
Desipramine may increase the QTc-prolonging activities of Moxifloxacin.
Moxonidine
The therapeutic efficacy of Moxonidine can be decreased when used in combination with Desipramine.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Desipramine.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Desipramine.
Naphazoline
Desipramine may decrease the antihypertensive activities of Naphazoline.
Naratriptan
The risk or severity of adverse effects can be increased when Naratriptan is combined with Desipramine.
Nateglinide
The metabolism of Nateglinide can be decreased when combined with Desipramine.
Nebivolol
The serum concentration of Nebivolol can be increased when it is combined with Desipramine.
Nefazodone
The risk or severity of adverse effects can be increased when Nefazodone is combined with Desipramine.
Nelfinavir
The serum concentration of Desipramine can be increased when it is combined with Nelfinavir.
Netupitant
The metabolism of Netupitant can be decreased when combined with Desipramine.
Nevirapine
The metabolism of Desipramine can be decreased when combined with Nevirapine.
Nialamide
Nialamide may increase the serotonergic activities of Desipramine.
Nicardipine
The metabolism of Nicardipine can be decreased when combined with Desipramine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Desipramine.
Nicorandil
Desipramine may increase the hypotensive activities of Nicorandil.
Nicotine
The metabolism of Nicotine can be decreased when combined with Desipramine.
Nicotine Polacrilex
The metabolism of Nicotine can be decreased when combined with Desipramine.
Nifedipine
The metabolism of Nifedipine can be decreased when combined with Desipramine.
Nilotinib
Desipramine may increase the QTc-prolonging activities of Nilotinib.
Nintedanib
The serum concentration of Nintedanib can be increased when it is combined with Desipramine.
Nitrazepam
The risk or severity of adverse effects can be increased when Nitrazepam is combined with Desipramine.
Nitrofurazone
The metabolism of Nitrofural can be decreased when combined with Desipramine.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Desipramine.
Norepinephrine
Desipramine may decrease the antihypertensive activities of Norepinephrine.
Norflurane
The risk or severity of adverse effects can be increased when Desipramine is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Desipramine is combined with Normethadone.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Desipramine.
O-PHENANTHROLINE
The serum concentration of Desipramine can be increased when it is combined with 1,10-Phenanthroline.
Ofloxacin
Desipramine may increase the QTc-prolonging activities of Ofloxacin.
Olanzapine
The metabolism of Olanzapine can be decreased when combined with Desipramine.
Olodaterol
The risk or severity of adverse effects can be increased when Desipramine is combined with Olodaterol.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Desipramine.
Omeprazole
The metabolism of Desipramine can be decreased when combined with Omeprazole.
Ondansetron
The metabolism of Ondansetron can be decreased when combined with Desipramine.
Opium
The risk or severity of adverse effects can be increased when Desipramine is combined with Opium.
Orphenadrine
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osimertinib
The serum concentration of Desipramine can be decreased when it is combined with Osimertinib.
Ospemifene
The metabolism of Ospemifene can be decreased when combined with Desipramine.
Oxazepam
The risk or severity of adverse effects can be increased when Oxazepam is combined with Desipramine.
Oxprenolol
The risk or severity of adverse effects can be increased when Desipramine is combined with Oxprenolol.
Oxycodone
The metabolism of Oxycodone can be decreased when combined with Desipramine.
Oxymetazoline
Desipramine may decrease the antihypertensive activities of Oxymetazoline.
Oxymorphone
The metabolism of Oxymorphone can be decreased when combined with Desipramine.
p-Hydroxyamphetamine
Desipramine may increase the stimulatory activities of Hydroxyamphetamine.
Paliperidone
Desipramine may decrease the antihypertensive activities of Paliperidone.
Palonosetron
The metabolism of Palonosetron can be decreased when combined with Desipramine.
Panobinostat
The serum concentration of Desipramine can be increased when it is combined with Panobinostat.
Pantoprazole
The metabolism of Desipramine can be decreased when combined with Pantoprazole.
Paraldehyde
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paregoric
The metabolism of Morphine can be decreased when combined with Desipramine.
Pargyline
Pargyline may increase the serotonergic activities of Desipramine.
Paroxetine
The risk or severity of adverse effects can be increased when Paroxetine is combined with Desipramine.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Desipramine.
Peginterferon Alfa-2b
The serum concentration of Desipramine can be decreased when it is combined with Peginterferon alfa-2b.
Pentamidine
The metabolism of Pentamidine can be decreased when combined with Desipramine.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Desipramine.
Pentobarbital
The metabolism of Desipramine can be increased when combined with Pentobarbital.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Perazine
The risk or severity of adverse effects can be increased when Desipramine is combined with Perazine.
Perflutren
Desipramine may increase the QTc-prolonging activities of Perflutren.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Desipramine.
Perhexiline
The metabolism of Perhexiline can be decreased when combined with Desipramine.
Periciazine
The risk or severity of adverse effects can be increased when Desipramine is combined with Propericiazine.
Perindopril
The serum concentration of Desipramine can be increased when it is combined with Perindopril.
Permethrin
The metabolism of Permethrin can be decreased when combined with Desipramine.
Perphenazine
The metabolism of Perphenazine can be decreased when combined with Desipramine.
Phenacetin
The metabolism of Phenacetin can be decreased when combined with Desipramine.
Phenelzine
Phenelzine may increase the serotonergic activities of Desipramine.
Phenformin
The metabolism of Phenformin can be decreased when combined with Desipramine.
Phenindione
Desipramine may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Desipramine can be increased when combined with Phenobarbital.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Desipramine is combined with Phenoxyethanol.
Phenprocoumon
Desipramine may increase the anticoagulant activities of Phenprocoumon.
Phentermine
Desipramine may increase the stimulatory activities of Phentermine.
PHENTERMINE RESIN
Desipramine may increase the stimulatory activities of Phentermine.
Phenylephrine
Desipramine may increase the vasopressor activities of Phenylephrine.
Phenylpropanolamine
The risk or severity of adverse effects can be increased when Desipramine is combined with Phenylpropanolamine.
Phenytoin
The metabolism of Desipramine can be increased when combined with Phenytoin.
Pimozide
Desipramine may increase the QTc-prolonging activities of Pimozide.
Pindolol
The metabolism of Pindolol can be decreased when combined with Desipramine.
Pipamperone
The risk or severity of adverse effects can be increased when Desipramine is combined with Pipamperone.
Piperazine
The metabolism of Piperazine can be decreased when combined with Desipramine.
Pipothiazine
The metabolism of Pipotiazine can be decreased when combined with Desipramine.
Pirbuterol
The risk or severity of adverse effects can be increased when Desipramine is combined with Pirbuterol.
Pirinitramide
The risk or severity of adverse effects can be increased when Desipramine is combined with Piritramide.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Desipramine.
Pizotyline
The risk or severity of adverse effects can be increased when Desipramine is combined with Pizotifen.
Pomalidomide
The risk or severity of adverse effects can be increased when Desipramine is combined with Pomalidomide.
Ponatinib
The metabolism of Ponatinib can be decreased when combined with Desipramine.
Pramipexole
Desipramine may increase the sedative activities of Pramipexole.
Pramoxine
The risk or severity of adverse effects can be increased when Desipramine is combined with Pramocaine.
Prasugrel
The metabolism of Prasugrel can be decreased when combined with Desipramine.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Desipramine.
Prazepam
The risk or severity of adverse effects can be increased when Desipramine is combined with Prazepam.
Pregabalin
The therapeutic efficacy of Desipramine can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of adverse effects can be increased when Desipramine is combined with Prilocaine.
Primaquine
Desipramine may increase the QTc-prolonging activities of Primaquine.
Primidone
The metabolism of Desipramine can be increased when combined with Primidone.
Procainamide
Desipramine may increase the QTc-prolonging activities of Procainamide.
Procaine
The risk or severity of adverse effects can be increased when Desipramine is combined with Procaine.
Procarbazine
Procarbazine may increase the serotonergic activities of Desipramine.
Procaterol
The risk or severity of adverse effects can be increased when Desipramine is combined with Procaterol.
Prochlorperazine
The metabolism of Prochlorperazine can be decreased when combined with Desipramine.
Progesterone
The metabolism of Progesterone can be decreased when combined with Desipramine.
Promazine
The metabolism of Desipramine can be decreased when combined with Promazine.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Desipramine.
Propafenone
The serum concentration of Desipramine can be increased when it is combined with Propafenone.
Proparacaine
The risk or severity of adverse effects can be increased when Desipramine is combined with Proparacaine.
Propofol
The metabolism of Propofol can be decreased when combined with Desipramine.
Propoxyphene
The risk or severity of adverse effects can be increased when Desipramine is combined with Dextropropoxyphene.
Propranolol
The metabolism of Propranolol can be decreased when combined with Desipramine.
Prothipendyl
The risk or severity of adverse effects can be increased when Desipramine is combined with Prothipendyl.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Desipramine.
Pseudoephedrine
Desipramine may decrease the antihypertensive activities of Pseudoephedrine.
Quazepam
The risk or severity of adverse effects can be increased when Quazepam is combined with Desipramine.
Quetiapine
Desipramine may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Desipramine may increase the QTc-prolonging activities of Quetiapine.
Quinapril
The serum concentration of Desipramine can be increased when it is combined with Quinapril.
Quinidine
Desipramine may increase the QTc-prolonging activities of Quinidine.
Quinine
Desipramine may increase the QTc-prolonging activities of Quinine.
Racecadotril
The serum concentration of Desipramine can be increased when it is combined with Racecadotril.
Ramelteon
The risk or severity of adverse effects can be increased when Ramelteon is combined with Desipramine.
Ramipril
The serum concentration of Desipramine can be increased when it is combined with Ramipril.
Ranitidine
The metabolism of Ranitidine can be decreased when combined with Desipramine.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Desipramine.
Rasagiline
Rasagiline may increase the serotonergic activities of Desipramine.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Desipramine.
Remoxipride
The metabolism of Remoxipride can be decreased when combined with Desipramine.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Desipramine.
Rifampin
The metabolism of Desipramine can be increased when combined with Rifampicin.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Desipramine.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Desipramine.
Risperidone
Desipramine may decrease the antihypertensive activities of Risperidone.
Ritodrine
The risk or severity of adverse effects can be increased when Desipramine is combined with Ritodrine.
Ritonavir
The metabolism of Desipramine can be decreased when combined with Ritonavir.
Rivaroxaban
The serum concentration of Desipramine can be increased when it is combined with Rivaroxaban.
Rizatriptan
The risk or severity of adverse effects can be increased when Rizatriptan is combined with Desipramine.
Rolapitant
The metabolism of Desipramine can be decreased when combined with Rolapitant.
Romidepsin
The metabolism of Romidepsin can be decreased when combined with Desipramine.
Ropinirole
Desipramine may increase the sedative activities of Ropinirole.
Ropivacaine
The metabolism of Ropivacaine can be decreased when combined with Desipramine.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Desipramine.
Rotigotine
Desipramine may increase the sedative activities of Rotigotine.
Rucaparib
The metabolism of Rucaparib can be decreased when combined with Desipramine.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Desipramine.
Salmeterol
The risk or severity of adverse effects can be increased when Desipramine is combined with Salmeterol.
Saquinavir
The serum concentration of Desipramine can be increased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Desipramine can be increased when it is combined with Saquinavir.
Saxagliptin
The serum concentration of Desipramine can be increased when it is combined with Saxagliptin.
Saxagliptin Anhydrous
The serum concentration of Desipramine can be increased when it is combined with Saxagliptin.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Desipramine.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Desipramine.
Secobarbital
The metabolism of Desipramine can be increased when combined with Secobarbital.
Selegiline
Selegiline may increase the serotonergic activities of Desipramine.
Sertindole
The metabolism of Sertindole can be decreased when combined with Desipramine.
Sertraline
The risk or severity of adverse effects can be increased when Sertraline is combined with Desipramine.
Sevoflurane
The metabolism of Sevoflurane can be decreased when combined with Desipramine.
Sildenafil
The metabolism of Sildenafil can be decreased when combined with Desipramine.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Desipramine.
Simeprevir
The serum concentration of Desipramine can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Desipramine.
Sitagliptin
The serum concentration of Desipramine can be increased when it is combined with Sitagliptin.
Sitagliptin Phosphate
The serum concentration of Desipramine can be increased when it is combined with Sitagliptin.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Sodium Phosphate
The risk or severity of adverse effects can be increased when Desipramine is combined with Sodium phosphate.
Sodium Phosphate, Monobasic
The risk or severity of adverse effects can be increased when Desipramine is combined with Sodium phosphate.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
The risk or severity of adverse effects can be increased when Desipramine is combined with Sodium phosphate.
Sorafenib
The metabolism of Sorafenib can be decreased when combined with Desipramine.
Sotalol
Desipramine may increase the QTc-prolonging activities of Sotalol.
Spirapril
The serum concentration of Desipramine can be increased when it is combined with Spirapril.
ST. JOHN'S WORT EXTRACT
The metabolism of Desipramine can be increased when combined with St. John's Wort.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Desipramine.
Sulfisoxazole
Desipramine may increase the QTc-prolonging activities of Sulfisoxazole.
Sulpiride
The risk or severity of adverse effects can be increased when Desipramine is combined with Sulpiride.
Sumatriptan
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Desipramine.
Sumatriptan Succinate
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Desipramine.
Suvorexant
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tamoxifen
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Desipramine resulting in a loss in efficacy.
Tamsulosin
The metabolism of Tamsulosin can be decreased when combined with Desipramine.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Tasimelteon
The risk or severity of adverse effects can be increased when Desipramine is combined with Tasimelteon.
Tedizolid
Tedizolid Phosphate may increase the serotonergic activities of Desipramine.
Tedizolid Phosphate
Tedizolid Phosphate may increase the serotonergic activities of Desipramine.
Tegaserod
The metabolism of Tegaserod can be decreased when combined with Desipramine.
Telaprevir
The serum concentration of Desipramine can be increased when it is combined with Telaprevir.
Telavancin
Desipramine may increase the QTc-prolonging activities of Telavancin.
Telithromycin
Desipramine may increase the QTc-prolonging activities of Telithromycin.
Temazepam
The metabolism of Temazepam can be decreased when combined with Desipramine.
Tenofovir Disoproxil
The metabolism of Desipramine can be decreased when combined with Tenofovir disoproxil.
Terbinafine
The metabolism of Desipramine can be decreased when combined with Terbinafine.
Terbutaline
The risk or severity of adverse effects can be increased when Desipramine is combined with Terbutaline.
Terbutaline Sulfate
The risk or severity of adverse effects can be increased when Desipramine is combined with Terbutaline.
Terfenadine
The metabolism of Terfenadine can be decreased when combined with Desipramine.
Teriflunomide
The serum concentration of Desipramine can be decreased when it is combined with Teriflunomide.
Testosterone
The metabolism of Testosterone can be decreased when combined with Desipramine.
Testosterone Cypionate
The metabolism of Testosterone cypionate can be decreased when combined with Desipramine.
Testosterone Enanthate
The metabolism of Testosterone enanthate can be decreased when combined with Desipramine.
Testosterone Undecanoate
The metabolism of Testosterone undecanoate can be decreased when combined with Desipramine.
Tetrabenazine
Desipramine may increase the QTc-prolonging activities of Tetrabenazine.
Tetracaine
The risk or severity of adverse effects can be increased when Desipramine is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Desipramine is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.
Thalidomide
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Theophylline
The metabolism of Desipramine can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Desipramine can be decreased when combined with Theophylline.
Thiamylal
The metabolism of Desipramine can be increased when combined with Thiamylal.
Thiopental
The metabolism of Desipramine can be increased when combined with Thiopental.
Thiopental Sodium
The metabolism of Desipramine can be increased when combined with Thiopental.
Thioproperazine
The risk or severity of adverse effects can be increased when Desipramine is combined with Thioproperazine.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Desipramine.
Thiothixene
The risk or severity of adverse effects can be increased when Thiothixene is combined with Desipramine.
Thyroid, Porcine
Thyroid, porcine may increase the arrhythmogenic activities of Desipramine.
Tiagabine
The risk or severity of adverse effects can be increased when Tiagabine is combined with Desipramine.
Tiapride
The risk or severity of adverse effects can be increased when Desipramine is combined with Tiapride.
Ticlopidine
The metabolism of Desipramine can be decreased when combined with Ticlopidine.
Timolol
The metabolism of Timolol can be decreased when combined with Desipramine.
Timolol Anhydrous
The metabolism of Timolol can be decreased when combined with Desipramine.
Tiotropium
The metabolism of Tiotropium can be decreased when combined with Desipramine.
Tipranavir
The metabolism of Desipramine can be decreased when combined with Tipranavir.
Tizanidine
Desipramine may decrease the antihypertensive activities of Tizanidine.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Desipramine.
Toloxatone
Toloxatone may increase the serotonergic activities of Desipramine.
Tolterodine
The metabolism of Tolterodine can be decreased when combined with Desipramine.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Desipramine.
Topiramate
The metabolism of Desipramine can be decreased when combined with Topiramate.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Desipramine.
Toremifene
Desipramine may increase the QTc-prolonging activities of Toremifene.
Trabectedin
The metabolism of Trabectedin can be decreased when combined with Desipramine.
Tramadol
Desipramine may increase the neuroexcitatory activities of Tramadol.
Trandolapril
The serum concentration of Desipramine can be increased when it is combined with Trandolapril.
Tranylcypromine
Tranylcypromine may increase the serotonergic activities of Desipramine.
Trazodone
The risk or severity of adverse effects can be increased when Trazodone is combined with Desipramine.
Tretinoin
The metabolism of Tretinoin can be decreased when combined with Desipramine.
Triazolam
The risk or severity of adverse effects can be increased when Triazolam is combined with Desipramine.
Triazulenone
The risk or severity of adverse effects can be increased when Desipramine is combined with Loprazolam.
Trifluoperazine
The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desipramine.
Triflupromazine
The risk or severity of adverse effects can be increased when Desipramine is combined with Triflupromazine.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Desipramine.
Triprolidine
The risk or severity of adverse effects can be increased when Triprolidine is combined with Desipramine.
Tropisetron
Tropisetron may increase the serotonergic activities of Desipramine.
Tryptophan
L-Tryptophan may increase the serotonergic activities of Desipramine.
Umeclidinium
The metabolism of Umeclidinium can be decreased when combined with Desipramine.
Urethane
The risk or severity of adverse effects can be increased when Desipramine is combined with Ethyl carbamate.
Valbenazine
The metabolism of Valbenazine can be decreased when combined with Desipramine.
Valproate
The serum concentration of Desipramine can be increased when it is combined with Valproic Acid.
Valproic Acid
The serum concentration of Desipramine can be increased when it is combined with Valproic Acid.
Vandetanib
Desipramine may increase the QTc-prolonging activities of Vandetanib.
Velpatasvir
The metabolism of Velpatasvir can be decreased when combined with Desipramine.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Desipramine.
Venlafaxine
The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desipramine.
Verapamil
The metabolism of Verapamil can be decreased when combined with Desipramine.
Vigabatrin
The risk or severity of adverse effects can be increased when Vigabatrin is combined with Desipramine.
Vilanterol
The risk or severity of adverse effects can be increased when Desipramine is combined with Vilanterol.
Vilazodone
The risk or severity of adverse effects can be increased when Vilazodone is combined with Desipramine.
Vildagliptin
The serum concentration of Desipramine can be increased when it is combined with Vildagliptin.
Vinblastine
The metabolism of Vinblastine can be decreased when combined with Desipramine.
Vincristine
The excretion of Vincristine can be decreased when combined with Desipramine.
Vinorelbine
The metabolism of Vinorelbine can be decreased when combined with Desipramine.
Voriconazole
The metabolism of Desipramine can be decreased when combined with Voriconazole.
Vortioxetine
The risk or severity of adverse effects can be increased when Vortioxetine is combined with Desipramine.
Warfarin
Desipramine may increase the anticoagulant activities of Warfarin.
Xylometazoline
Desipramine may decrease the antihypertensive activities of Xylometazoline.
Yohimbine
The serum concentration of Yohimbine can be increased when it is combined with Desipramine.
Zalcitabine
The metabolism of Zalcitabine can be decreased when combined with Desipramine.
Zaleplon
The risk or severity of adverse effects can be increased when Zaleplon is combined with Desipramine.
Ziconotide
The risk or severity of adverse effects can be increased when Desipramine is combined with Ziconotide.
Ziprasidone
Desipramine may increase the QTc-prolonging activities of Ziprasidone.
Zofenopril
The serum concentration of Desipramine can be increased when it is combined with Zofenopril.
Zolmitriptan
The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Desipramine.
Zolpidem
Desipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide
The risk or severity of adverse effects can be increased when Zonisamide is combined with Desipramine.
Zopiclone
The risk or severity of adverse effects can be increased when Zopiclone is combined with Desipramine.
Zotepine
The risk or severity of adverse effects can be increased when Desipramine is combined with Zotepine.
Zuclopenthixol
Desipramine may increase the QTc-prolonging activities of Zuclopenthixol.
